Key Findings:  This mouse model of inflammatory bowel disease (IBD) and Crohn's Disease (CD) identified cannabinoid 2 receptors (CB2R) in abundance on immune cells, especially CD4+T. Targeting this mechanism of inflammation may lead to future therapeutic treatments to reduce the inflammation associated with IBD.
Type of Study:  Animal Study
Study Result:  Positive
Study Location(s):  Germany, United States
Year of Pub:  2017
Cannabinoids Studied:  Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified), Other Related Compounds, Palmitoylethanolamide (PEA)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2, GPCR 55, TRPV1, GPCR, TRPs
Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines